{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:43:06Z","timestamp":1777394586867,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA","award":["HO-19-19871"],"award-info":[{"award-number":["HO-19-19871"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s41669-022-00329-3","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:04:26Z","timestamp":1646647466000},"page":"509-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Direct Medical Costs of Four Vaccine-Preventable Infectious Diseases in Older Adults in Spain"],"prefix":"10.1007","volume":"6","author":[{"given":"\u00c1ngel","family":"Gil de Miguel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Eiros Bouza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Ignacio","family":"Mart\u00ednez Alcorta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-1258","authenticated-orcid":false,"given":"Daniel","family":"Callejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Mi\u00f1arro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8579-0835","authenticated-orcid":false,"given":"Laura Amanda","family":"Vallejo-Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Tafalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0241-6566","authenticated-orcid":false,"given":"Mar\u00eda del Rosario","family":"Cambronero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Martin-Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"issue":"9","key":"329_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1473-3099(18)30478-X","volume":"18","author":"HC Turner","year":"2018","unstructured":"Turner HC, Thwaites GE, Clapham HE. Vaccine-preventable diseases in lower-middle-income countries. Lancet Infect Dis. 2018;18(9):937\u20139. https:\/\/doi.org\/10.1016\/S1473-3099(18)30478-X.","journal-title":"Lancet Infect Dis"},{"key":"329_CR2","unstructured":"World Health Organization (WHO). Immunization. 2019. https:\/\/www.who.int\/news-room\/facts-in-pictures\/detail\/immunization. Accessed 09 Aug 2021."},{"issue":"4","key":"329_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40520-019-01443-9","volume":"33","author":"J Gaillat","year":"2021","unstructured":"Gaillat J. Where are the keys to improve vaccine uptake in adults and elders in European countries? Aging Clin Exp Res. 2021;33(4):1123\u201331. https:\/\/doi.org\/10.1007\/s40520-019-01443-9.","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"329_CR4","first-page":"84","volume":"68","author":"T F\u00fcl\u00f6p","year":"2016","unstructured":"F\u00fcl\u00f6p T, Dupuis G, Witkowski JM, Larbi A. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016;68(2):84\u201391.","journal-title":"Rev Invest Clin"},{"issue":"7","key":"329_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1086\/529197","volume":"46","author":"B Weinberger","year":"2008","unstructured":"Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078\u201384. https:\/\/doi.org\/10.1086\/529197.","journal-title":"Clin Infect Dis"},{"key":"329_CR6","unstructured":"Eurostat. Causes of death statistics\u2014people over 65. 2020. https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Causes_of_death_statistics_-_people_over_65. Accessed 09 Aug 2021."},{"key":"329_CR7","doi-asserted-by":"publisher","unstructured":"Heron M. Deaths: leading causes for 2019. National Center for Health Statistics (U.S.). Division of Vital Statistics. 2021;70(9). https:\/\/doi.org\/10.15620\/cdc:107021. Accessed 09 Aug 2021.","DOI":"10.15620\/cdc:107021"},{"key":"329_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n188","volume":"372","author":"AL Cunningham","year":"2021","unstructured":"Cunningham AL, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for older adults. BMJ. 2021;372: n188. https:\/\/doi.org\/10.1136\/bmj.n188.","journal-title":"BMJ"},{"key":"329_CR9","unstructured":"D\u00edaz JP, Garc\u00eda AA, Nieto PA, Fari\u00f1as DR. Informes Envejecimiento en red n\u00ba 25, 39p. Un perfil de las personas mayores en Espa\u00f1a, 2020. Indicadores estad\u00edsticos b\u00e1sicos 2020. http:\/\/envejecimiento.csic.es\/documentos\/documentos\/enred-indicadoresbasicos2020.pdf. Accessed 01 June 2021."},{"key":"329_CR10","unstructured":"Instituto Nacional de Estad\u00edstica. 4.1. Esperanza de vida. 2020. https:\/\/www.ine.es\/ss\/Satellite?c=INESeccion_C&cid=1259926380048&p=1254735110672&pagename=ProductosYServicios%2FPYSLayout Accessed 09 Aug 2021."},{"key":"329_CR11","unstructured":"OECD\/European Union. Health at a Glance: Europe 2020: State of Health in the EU Cycle. 2020. https:\/\/ec.europa.eu\/health\/sites\/default\/files\/state\/docs\/2020_healthatglance_rep_en.pdf. Accessed 01 June 2021."},{"issue":"36","key":"329_CR12","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1016\/j.vaccine.2021.07.029","volume":"39","author":"J Carrico","year":"2021","unstructured":"Carrico J, Talbird SE, La EM, Poston S, Poirrier J-E, DeMartino JK, et al. Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population. Vaccine. 2021;39(36):5187\u201397. https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.029.","journal-title":"Vaccine"},{"issue":"4","key":"329_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","volume":"36","author":"JM McLaughlin","year":"2015","unstructured":"McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36(4):259\u201373. https:\/\/doi.org\/10.1007\/s10935-015-0394-3.","journal-title":"J Prim Prev"},{"key":"329_CR14","unstructured":"Consejo Interterritorial. Sistema Nacional de Salud. Calendario com\u00fan de vacunaci\u00f3n a lo largo de toda la vida. Calendario recomendado a\u00f1o 2021. 2021. https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/docs\/CalendarioVacunacion_Todalavida.pdf. Accessed 24 Nov 2021."},{"key":"329_CR15","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Tabla coberturas de vacunaci\u00f3n frente a gripe en \u2265 65 a\u00f1os, personas de 60\u201364 a\u00f1os, embarazadas y personal sanitario. Comunidades Aut\u00f3nomas. Campa\u00f1a 2018\u20132019. https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/coberturas\/docs\/Tabla13.pdf. Accessed 31 May 2021."},{"key":"329_CR16","unstructured":"Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontologia. Recomendaciones de vacunaci\u00f3n para adultos y mayores y calendarios vacunales 2019\u20132020. https:\/\/www.segg.es\/media\/descargas\/VACUNAS-SEGG-2019-2020.pdf. Accessed 31 May 2021."},{"key":"329_CR17","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Tabla evoluci\u00f3n coberturas de primovacunaci\u00f3n. Espa\u00f1a, 2009\u20132019. https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/coberturas\/docs\/Tabla1.pdf. Accessed 31 May 2021."},{"key":"329_CR18","unstructured":"Ministerio de Sanidad. Portal estadistico. Area de Inteligencia de Gestion. Conjunto M\u00ednimo B\u00e1sico de Datos\u2014Hospitalizaci\u00f3n (CMBD-H). Desde 1997 hasta 2015 incluido. https:\/\/pestadistico.inteligenciadegestion.mscbs.es\/publicoSNS\/N\/rae-cmbd\/cmbd-h. Accessed 01 June 2021."},{"key":"329_CR19","unstructured":"Ministerio de Sanidad. Portal estadistico. Area de Inteligencia de Gestion. Base de Datos de Cl\u00ednicos de Atenci\u00f3n Primaria (BDCAP). https:\/\/pestadistico.inteligenciadegestion.mscbs.es\/publicoSNS\/S\/base-de-datos-de-clinicos-de-atencion-primaria-bdcap. Accessed 03 June 2021."},{"key":"329_CR20","unstructured":"Centers for Disease Control and Prevention. National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 2015. https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm. Accessed 01 June 2021."},{"key":"329_CR21","unstructured":"Ministerio de Sanidad, Pol\u00edtica Social e Igualdad. Informacion y Estadisticas sanitarias 2011. Clasificaci\u00f3n Internacional de Enfermedades. 9\u00aa Revisi\u00f3n Modificaci\u00f3n Cl\u00ednica (CIE-9-MC). 8\u00aa Edici\u00f3n. 2012. https:\/\/www.mscbs.gob.es\/estadEstudios\/estadisticas\/docs\/CIE9MC_8ed.pdf. Accessed 01 June 2021."},{"key":"329_CR22","unstructured":"Ministerio de Sanidad. BDCAP. Base de Datos Cl\u00ednicos de Atenci\u00f3n Primaria. Ficha t\u00e9cnica\u2014Datos 2018. 2018. https:\/\/www.mscbs.gob.es\/estadEstudios\/estadisticas\/estadisticas\/estMinisterio\/SIAP\/Ficha_tecnica_BDCAP_2018.pdf. Accessed 09 Aug 2021."},{"key":"329_CR23","unstructured":"World Health Organization. International Classification of Primary Care, 2nd edition (ICPC-2). 2021. https:\/\/www.who.int\/standards\/classifications\/other-classifications\/international-classification-of-primary-care. Accessed 03 June 2021."},{"key":"329_CR24","unstructured":"Oblikue Consulting S.L. Spanish Health Costs and cost-effectiveness ratios Database: eSalud. http:\/\/oblikue.com\/bddcostes\/. Accessed 03 June 2021."},{"issue":"4","key":"329_CR25","first-page":"333","volume":"32","author":"E Bouza","year":"2019","unstructured":"Bouza E, Ancochea-Berm\u00fadez J, Campins M, Eir\u00f3s-Bouza JM, Fargas J, Rojas AG, et al. The situation of vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain. Rev Esp Quimioter. 2019;32(4):333\u201364.","journal-title":"Rev Esp Quimioter"},{"issue":"5","key":"329_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1157\/13092984","volume":"38","author":"XB Llach","year":"2006","unstructured":"Llach XB, Gamisans MR, Tudel JMF, Sanz CA, Rubio TC. Study of flu costs. Aten Primaria. 2006;38(5):260\u20137. https:\/\/doi.org\/10.1157\/13092984.","journal-title":"Aten Primaria"},{"key":"329_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01717-7","author":"J D\u00edez-Domingo","year":"2021","unstructured":"D\u00edez-Domingo J, Curran D, Cambronero MdR, Garcia-Martinez J-A, Matthews S. Economic burden and impact on quality of life of Herpes Zoster in Spanish adults aged 50\u00a0years or older: a prospective cohort study. Adv Ther. 2021. https:\/\/doi.org\/10.1007\/s12325-021-01717-7.","journal-title":"Adv Ther"},{"issue":"7","key":"329_CR28","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1080\/21645515.2016.1143577","volume":"12","author":"R Gil-Prieto","year":"2016","unstructured":"Gil-Prieto R, Pascual-Garcia R, Walter S, \u00c1lvaro-Meca A, Gil-De-Miguel \u00c1. Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study. Hum Vaccin Immunother. 2016;12(7):1900\u20135. https:\/\/doi.org\/10.1080\/21645515.2016.1143577.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"329_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00431-013-2228-8","volume":"173","author":"MI Fern\u00e1ndez-Cano","year":"2014","unstructured":"Fern\u00e1ndez-Cano MI, Armadans Gil L, Mart\u00ednez G\u00f3mez X, Campins MM. Incidence of whooping cough in Spain (1997\u20132010): an underreported disease. Eur J Pediatr. 2014;173(6):721\u20136. https:\/\/doi.org\/10.1007\/s00431-013-2228-8.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"329_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4161\/hv.36156","volume":"11","author":"I Crespo","year":"2015","unstructured":"Crespo I, Broner S, Soldevila N, Mart\u00ednez A, Godoy P, Sala-Farr\u00e9 M-R, et al. Characteristics of pertussis outbreaks in Catalonia, Spain, 1997 to 2010. Hum Vaccin Immunother. 2015;11(1):231\u20135. https:\/\/doi.org\/10.4161\/hv.36156.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"329_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/14760584.2019.1588727","volume":"18","author":"W Kandeil","year":"2019","unstructured":"Kandeil W, Atanasov P, Avramioti D, Fu J, Demarteau N, Li X. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines. 2019;18(5):439\u201355. https:\/\/doi.org\/10.1080\/14760584.2019.1588727.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"329_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eimc.2012.12.011","volume":"31","author":"M Campinsa","year":"2013","unstructured":"Campinsa M, Moreno-P\u00e9rez D, Gil-de Miguel A, Gonz\u00e1lez-Romo F, Moraga-Llop FA, Ar\u00edstegui-Fern\u00e1ndez J, et al. Tos ferina en Espa\u00f1a. Situaci\u00f3n epidemiol\u00f3gica y estrategias de prevenci\u00f3n y control. Recomendaciones del Grupo de Trabajo de Tos ferina [Whooping cough in Spain. Current epidemiology, prevention and control strategies. Recommendations by the Pertussis Working Group]. Enferm Infect Microbiol Clin. 2013;31(4):240\u201353. https:\/\/doi.org\/10.1016\/j.eimc.2012.12.011.","journal-title":"Enferm Infect Microbiol Clin."},{"key":"329_CR33","first-page":"e1","volume":"95","author":"J Masa-Calles","year":"2021","unstructured":"Masa-Calles J, L\u00f3pez-Perea N, Cordero BV, Carmona R. Vigilancia y epidemiolog\u00eda del herpes z\u00f3ster en Espa\u00f1a. Rev Esp Salud P\u00fablica. 2021;95:e1-13.","journal-title":"Rev Esp Salud P\u00fablica."},{"key":"329_CR34","unstructured":"Centro Nacional de Epidemiolog\u00eda. CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP). Instituto de Salud Carlos II. Resultados de la Vigilancia Epidemiol\u00f3gica de las enfermedades transmisibles. Informe anual. A\u00f1o 2015. 2017. https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/INFORMES\/INFORMES%20RENAVE\/RENAVE_INFORME_ANUAL_2015.pdf. Accessed 23 Nov 2021."},{"key":"329_CR35","unstructured":"Red Nacional de Vigilancia Epidemiol\u00f3gica. Instituto de Salud Carlos III. Ministerio de Ciencia e Innovaci\u00f3n. Resultados de la Vigilancia Epidemiol\u00f3gica de las enfermedades transmisibles. Informe anual. A\u00f1os 2017\u20132018. 2020. https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/INFORMES\/INFORMES%20RENAVE\/ultimo%20informe.pdf. Accessed 23 Nov 2021."},{"key":"329_CR36","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Vacunas y Programa de Vacunaci\u00f3n. 2021. https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/coberturas\/home.htm. Accessed 23 Nov 2021."},{"key":"329_CR37","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Coberturas de Vacunaci\u00f3n. Datos Estad\u00edsticos. 2021. https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/coberturas\/home.htm. Accessed 09 June 2021."},{"key":"329_CR38","unstructured":"Instituto Nacional de Estad\u00edstica. \u00cdndices nacionales: general y de grupos ECOICOP. 2021. https:\/\/www.ine.es\/jaxiT3\/Tabla.htm?t=22344. Accessed 23 Nov 2021."},{"issue":"3","key":"329_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7326\/M16-2936","volume":"166","author":"DK Kim","year":"2017","unstructured":"Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med. 2017;166(3):209\u201319. https:\/\/doi.org\/10.7326\/M16-2936.","journal-title":"Ann Intern Med"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00329-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00329-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00329-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:51:58Z","timestamp":1657785118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00329-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00329-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"1 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GlaxoSmithKline Biologicals SA funded this study\/research [GSK study identifier HO-19-19871] and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took in\u00a0charge of all costs associated with the development and publication of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"\u00c1ngel Gil de Miguel, Jos\u00e9 Mar\u00eda Eiros Bouza and Luis Ignacio Mart\u00ednez Alcorta declare they have received consulting fees from the GSK group of companies, during the conduct of the study. Luis Ignacio Mart\u00ednez Alcorta declares receiving lecturing fees from Merck Sharp & Dohme Corp, outside the submitted work. Daniel Callejo and Carlos Mi\u00f1arro are employed by IQVIA, which received funding from the GSK group of companies for the conduct of this study. Laura Amanda Vallejo-Aparicio, Andrea Garc\u00eda, M\u00f3nica Tafalla, M del Rosario Cambronero, Rub\u00e9n Rodr\u00edguez and Laura Martin-Gomez are employed by the GSK group of companies. Laura Amanda Vallejo-Aparicio, M\u00f3nica Tafalla, M. del Rosario Cambronero, Rub\u00e9n Rodr\u00edguez and Laura Martin-Gomez hold shares in the GSK group of companies. M\u00f3nica Tafalla was a GSK employee when the study was conducted. All authors declare no other financial or non-financial relationships and activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"GSK makes available anonymised individual participant data and associated documents from interventional clinical studies which evaluate medicines, upon approval of proposals submitted to . To access data for other types of GSK-sponsored research, for study documents without patient-level data and for clinical studies not listed, please submit an enquiry via the website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AGdM, JMEB, DC, CM, AG, MT, RR and LM-G participated in the conception or the design of the study. AGdM, DC, LAV-A and CM participated in the collection or generation of the data. All authors were involved in the analyses or interpretation of the data and the development of this manuscript. All authors had full access to the data and gave final approval before submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"This is a health economics study using aggregated data sourced from public databases, not using patient-level data, so no ethical consideration was applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable as no individual-related data were used in this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as no individual-related data were used in this study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sociedad Espa\u00f1ola de Epidemiologia\u2014XXXIX Reuni\u00f3n Cient\u00edfica 2021.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Congress presentation"}}]}}